Oxfordshire CCG Service Specification Management of Venous and Mixed Aetiology Leg Ulcers Requiring Compression Therapy

Size: px
Start display at page:

Download "Oxfordshire CCG Service Specification Management of Venous and Mixed Aetiology Leg Ulcers Requiring Compression Therapy"

Transcription

1 Oxfrdshire CCG Service Specificatin Management f Venus and Mixed Aetilgy Leg Ulcers Requiring Cmpressin Therapy 1. Backgrund Current best practice and natinal guidelines recmmend the use f high cmpressin therapy fr patients wh have leg ulceratin due t venus disease. In many cases, fllwing a rbust assessment, it is als pssible t manage patients with mixed aetilgy disease (venus and arterial causes) with mdified cmpressin. It is recgnised that the treatment f this grup f patients requires a specialist level f knwledge and skill and can be time cnsuming. Under this specificatin, GP practices will be ffered payment fr treating patients wh have venus leg ulceratin which is suitable fr high cmpressin therapy r wh have leg ulcers f mixed aetilgy (arterial and venus) which are suitable fr mdified cmpressin therapy. As part f essential services in the GMS cntract, practices shuld cntinue t identify and prevent, as far as pssible, the develpment f leg ulcers in all patients cnsidered t be at high risk. This wuld include patients with previus leg ulcer histry and thse shwing signs and symptms f venus disease (as per CEAP classificatin tl) such as varicse eczema, varicse veins and dependant edema. 2. Aims The aim f the service is t apprpriately manage the care f patients with new and existing leg ulceratin wh wuld benefit frm cmpressin therapy. The bjectives f the service are t: T prvide nursing assessment and diagnsis f leg ulcer aetilgy fr ambulant patients T prvide n-ging treatment and evaluatin up t healing T prvide supprt fr aftercare and preventin f reccurrence f ulceratin T prvide educatinal advice t supprt patients in the management f their skin 3. Service descriptin The service will prvide: A full and hlistic assessment f a patient with leg ulceratin t assess their suitability fr high cmpressin therapy r mdified cmpressin therapy. This will include the use f Dppler ultrasund as a diagnstic tl. Onging cmpressin therapy in 12 weekly cycles with reassessment every 12 weeks. Reassessment appintments will be paid at the higher rate. Fr venus leg ulcers, an individualised treatment plan based n the lcal Tissue Viability Service Venus Leg Ulcer Pathway (attached at Appendix 4) which reflects natinal guidelines and evidenced best practice as set ut at Versin

2 Regular dressings and cmpressin therapy accrding t an individualised treatment plan and in line with Oxfrdshire s wund dressing frmulary Onging review and reassessment and referrals where apprpriate t specialists, e.g. Specialist Tissue Viability service, Dermatlgy r Vascular services. Supprt frm the Specialist Tissue Viability service at Oxfrd Health NHS Fundatin Trust fr advice and specialist assessment (see referral frm at Appendix 2) as fllws: Venus Leg Ulcers If the venus leg ulcer des nt appear t be respnding t the management plan/ cmpressin therapy after 6 weeks f treatment (apprx. 40% reductin in wund area), the patient shuld be discussed with the cmmunity Specialist Tissue Viability Nurse via service, xfrdhealth.tissueviability@nhs.net (NHS net t NHS net s are secure.) If the leg ulcer des nt appear t be respnding t cmpressin therapy after 12 weeks f treatment (apprx. further 40% reductin in wund area), the patient shuld be referred t the Specialist Tissue Viability Nurse, r jintly assessed with the cmmunity Specialist Tissue Viability Nurse (See referral frm, appendix 2) Between 12 and 24 weeks f treatment practices shuld cntinue t manage the leg ulcer, seeking advice frm the cmmunity Specialist Tissue Viability Nurse as required. It is anticipated that apprximately 70% f venus leg ulcers will be healed at 24 weeks, with a further 20% prgressing well twards healing. A minrity f wunds, apprx. 10%, can be expected t be slw t heal and will need nging management. Mixed Venus & Arterial Leg ulcers If the leg ulcer des nt appear t be respnding t a management plan/ mdified cmpressin therapy after 6 weeks f treatment (apprx % reductin in wund area), the patient shuld be discussed with the Specialist Tissue Viability Nurse via the tissue viability service, xfrdhealth.tissueviability@nhs.net If the leg ulcer des nt appear t be respnding t a management plan/ mdified cmpressin therapy after 12 weeks f treatment (apprx. further 10 20%% reductin in wund area), the patient shuld be referred t the cmmunity Specialist Tissue Viability Nurse, r jintly assessed with the Specialist Tissue Viability Nurse (see referral frm Appendix 2). Frm 12 weeks, practices shuld cntinue t manage the mixed aetilgy leg ulcer, seeking advice frm the cmmunity Specialist Tissue Viability Nurse as required. Due t the nature f the disease, this grup f patients will be slwer t heal and may require vascular interventin. Cmmunity tissue viability will advise practices n this. Patient educatin and lifestyle management with written supprt fr patients and carers. The service prvider will ensure that: Versin

3 Patients with leg ulceratin receive a cmprehensive hlistic assessment that includes the use f Dppler ultrasund as a diagnstic tl. Patients receiving treatment are regularly reassessed every 12 weeks. Essential Dppler ultrasund equipment is available within the practice, and maintained accrding t manufacturer s instructins. All clinicians prviding the service have cmpleted the relevant training curse and are prficient and cmpetent in the care f peple with leg ulceratin, including the use f Dppler and cmpressin bandaging. Premises are suitable fr the prvisin f treatment t patients with leg ulcers, including the implementatin f the standards fr infectin cntrl and the safe dispsal f cntaminated waste. The service cntinues t be prvided during perids f staff absences thrugh illness r annual leave. Practices must make their wn arrangements fr cver ensuring it meets the criteria set ut in this specificatin. Accurate and clear recrds are maintained. This must include the treatment and quantity f the dressings rdered fr the patient. A patient lg t be kept by all prviders f the service This service is nly available t patients wh are registered with the prvider s wn practice. Accreditatin The Prvider will ensure that all clinical staff prviding this service have cmpleted relevant training in the management f leg ulcers, and are prficient and cmpetent in the care f peple with leg ulceratin, including skills in the use f Dppler and cmpressin bandaging. Nurses wh have nt cmpleted such training as at 1 st April 2014 are required t undertake the 2-day training curse n the management f leg ulcers prvided by Oxfrd Health via their Learning and Develpment Department by 31 st Octber Evaluatin and audit f primary care leg ulcer services will be undertaken regularly t ensure that quality and standards, within the cntext f clinical gvernance, are being maintained. Supply f dressings Please nte that all dressings must be used in line with the wund care frmulary (attached at Appendix 3) which has been prduced jintly with Oxfrd Health NHS Fundatin Trust. Dressings used in the delivery f this service must be rdered via the ONPOS system except as indicated in the Frmulary. Any additinal prescribing csts fr this will be taken int accunt when mnitring the practice's prescribing budget. 4. Payment Practices will be paid fr the fllwing:. 1. First assessment (includes 30 per leg 2. Further appintments fr up t per treatment per leg 3. If nt healed, reassessment at 13 weeks (includes 30 per leg 4. Further appintments fr up t per treatment per leg Versin

4 5. If nt healed, reassessment at 25 weeks (includes 30 per leg 6. Further appintments fr up t per treatment per leg 7. If nt healed, reassessment at 37 weeks (includes 30 per leg This is based n a reassessment after each 12 week cycle if a patient s leg ulcer has nt satisfactrily healed; the practice may make a secnd & third claim, but may be expected t prvide additinal details. It is anticipated that many patients will need nce-weekly treatments, hwever, where treatment is required mre than nce a week, the practice may claim fr each appintment. The practice clinical lead fr this service will be expected t mnitr the frequency f treatments t ensure that they are clinically apprpriate. Practices wh have higher than average levels f multiple appintments may be asked fr further infrmatin t clarify reasns fr this. Practices are expected t recrd when cmpressin therapy finishes (including mdified cmpressin therapy) using the cdes shwn in Appendix 1 belw. If a patient has leg ulcers n bth legs, the practice may claim fr tw separate payments. In rder t maintain skill levels, practitiners will be expected t care fr a minimum f 12 treatments requiring cmpressin therapy per year. These payments d nt include the cst f dressings which are btained via the ONPOS system and medicatin which is n prescriptin 5. Mnitring Practices are asked t submit a quarterly reprt using QUEST f actual activity t the CCG by the 15 th f the mnth fllwing the end f each quarter during the year. The quarterly activity reprts will frm the basis f payments. Read cdes t be used fr this service are shwn at Appendix 1 belw. 7. Terminatin This service will terminate n 31 st March Any change t the service r earlier terminatin f the agreement must be agreed by bth Cmmissiner and Prvider. Versin

5 Appendix 1: Read Cdes fr Leg Ulcer Care Search Ppulatin Item Patients with a Venus Leg Ulcer Patients with a Mixed Venus and Arterial Leg Ulcer Read Cde and Descriptin M2715 Venus ulcer f leg M2714 Mixed Venus and Arterial ulcer f leg Fr Level 1 30 (Initial assessment) Fr Level 1 30 (Reassessment) Initial assessment in primary care leg ulcer clinic and cmpressin therapy started Re-assessment at 12-week intervals, seen in primary care leg ulcer clinic and cmpressin therapy cntinued 8CV2. Leg ulcer cmpressin therapy started 38C4. Leg ulcer assessment Fr Level 2 15 (Onging care) Seen in leg ulcer clinic fr nging cmpressin therapy 9N0t. Seen in primary care leg ulcer clinic Fr infrmatin Leg ulcer cmpressin therapy finished 8CT1 Leg ulcer cmpressin therapy finished Versin

6 Appendix 2: Cmplex Wund Referral Frm Office Use Only : Received: Respnded: Visit: COMPLEX WOUND REFERRAL FORM Please cmplete in blck capitals and give as much infrmatin as pssible. Date f Referral PATIENTS Name N.H.S N. D.O.B PATIENTS Address Pstcde Tel. N. Address if different frm abve G.P Name Surgery address GP Tel. Inc.STD Referred by Name Jb Title Tel. inc. STD Fax N. E.mail Reasn fr referral Is referral due t a serius incident requiring investigatin? Y N Lcatin f wunds and number f wunds Type f wunds Pressure Ulcer Diabetic Ulcer Traumatic wund Burn / scald Surgical wund Fungating lesin Leg ulcer Other please state Wund duratin Days.. Weeks... Years. Versin

7 Factrs which culd delay healing Immbility / Seating Diabetes Pr Nutritinal status Old Age Dehydratin Incntinence Infectin. Anaemia Misture Ischaemia If leg ulcer ABPI L Leg R Leg ABPI = ABPI = Date f ABPI Lcal wund bed Systemic (Cellulitis) Current Blds Hb... Glucse... Date Wund Assessment Wund size in cm2 Length in cm.. Width in cm Depth in cm/mm Wund bed tissue type Black % necrtic Green % infected Yellw % slugh Red % granulating Pink % epithelialising EXUDATE levels Nne Lw Mderate High Cntinued. Aut Immune Cnditin i.e. Rheumatid Arthritis. Smking Allergies- (please state) Nn Cncrdance Drug Therapy e.g. Sterids, Immunsuppressant, Anticagulant, Anti- inflammatry analgesics. (please state).. End f life/palliative Care Other (please state). Current dressing regime cmmenced date Primary dressing used Secndary dressing used Cmpressin bandages (if applicable). Frequency f dressing change.. Hw lng used?... Surrunding skin Oedema Erythematic Macerated Healthy / Intact Wund Odur YES NO Pain scre I I I I I Exudate type Serus Haemserus Purulent Versin

8 Has a wund r Leg ulcer assessment been cmpleted: W. assessment Y N L.U. assessment Y N Wund traced/measured Y N Phtgraphed Y N Up t date Dppler (if LU) Y N Key Reasn fr Referral, List key Management challenges IF REFERRAL RESULTS IN A TV VISIT WE WOULD EXPECT A NURSE WHO UNDERSTANDS THE PATIENT CASE TO BE PRESENT DURING THE CONSULTATION Please cmplete frm fully and send t Tissue Viability either by t tissueviability@xfrdhealth.nhs.uk r if frm a GP practice/nhs.net accunt please use xfrdhealth.tissueviability@nhs.net r fax t N. B. Frms that are cnsidered illegible r incmplete will be returned t sender. Versin

9 Appendix 3: Wund Management Advice and Prescribing Guidance Versin

10 Versin

11 Appendix 4: Venus Leg Ulcer Standard and Cmplex Pathways Venus Leg Ulcer Pathway 1 (Standard) 24 week healing target (Please refer t the guidance n the reverse f this pathway algrithm) Initial leg ulcer Assessment Diagnsis f venus ulceratin (ABPI ) Enter assessment cde & venus leg ulcer cde n RIO Free frm devitalised tissue and infectin Wund slughy but nt lcally infected Lcal wund infectin (with r withut slugh) Treat with Urgclean, absrbent pad and apprpriate cmpressin until wund bed clean. If debridement nt achieved within 2 weeks then refer t Tissue Viability fr advice Treat with Antimicrbial as per frmulary, absrbent pad and apprpriate cmpressin fr 2 weeks. Refer t T.V if wund still appears infected after 2 weeks Treat with Atrauman, absrbent pad & apprpriate cmpressin Re assess every 6 weeks Map and measure wund surface area in cm² Fllwing expected healing prgressin (Has achieved at least a 40% reductin in wund surface area) Nt fllwing expected healing prgressin (<40% reductin in surface area f wund in 6 weeks) Cntinue with VLU Pathway 1 Healed Enter healed cde n RiO and cmmence patient n healed leg care plan Mve t VLU Pathway 2 (Cmplex) Refer t tissue viability if supprt required at this pint Versin

12 Guidance fr Standard venus leg ulcer pathway (See criteria fr pathway allcatin) All f the supprting dcumentatin can be accessed/ dwnladed frm the tissue viability prtal n the intranet (insert link) N Actin t be taken Dcuments/Guidance/ tls t supprt actin 1 Venus aetilgy shuld be established by carrying ut a full Leg ulcer plicy & guidelines leg ulcer assessment which shuld include a Dppler Leg ulcer assessment frm assessment. Make sure yu have traced the ulcer/s and Wund prgressin chart wrked ut surface area in cm² Guide t measuring wund surface area Dcument assessment findings in patients ntes Lwer limb assessment frm Dppler assessment frm *Allcate t this pathway if the patients ulcer is less than 6 Wund healing pathway/ risk tl mnths ld, ulcer/s size ttals less than 100cm² and ulcer is NOT a recurrence 2 Dppler assessment - Ensure ABPI is between befre Guide t carrying ut a Dppler implementing pathway NB Cnsider falsely elevated readings in Guide t interpreting ABPI elderly pts, particularly with diabetes & renal disease. 3 Enter assessment cde & venus leg ulcer cde n RiO Standard perating prcedure fr entering leg ulcer cdes n RIO Allcate patient t PSAG (Pt Status at a Glance) bard. Advice sheet - PSAG 4 Assess wund bed fr signs f lcal wund bed infectin Guidance fr the assessment & management f bacterial lading in wunds AMBL tl fr assessing fr lcal infectin 5 Urgclean prduct guide If wund bed is clnised/ slughy the primary dressing Gd prescribing guidelines shuld be Urgclean. This prduct has hydr-deslughing fibres that trap slughy residues. It prvides an nn adherent / atraumatic cntact layer. Use fr up t 2 weeks nly. If wund is nt deslughing, cntact tissue viability fr advice. 6 If wund bed is lcally infected cmmence 2 weeks curse f a Antimicrbial frmulary tpical antimicrbial treatment. Antimicrbial frmulary summary sheet 1 st line Hney Inf sheet Patients guide t Hney 2 nd line Cadexmer idine These prducts need prescribing (Nt available frm ONPOS). Prduct Inf sheets Dressings (T include PIP cdes fr prescribing) Only prescribe the number f dressings required fr a 2 week Gd prescribing guidance. curse. Dcument start and stp dates f treatment in patient s ntes. 7 If wund is free frm slugh and/ r lcal infectin cmmence Atrauman as yur primary cntact layer Prduct guide t Atrauman 8 Chse an absrbent pad as a secndary dressing based n the level f exudate present in the wund. NB If yu have t step up t Srbin, this is 2 nd line s will need t be prescribed. *Remember t STEP DOWN when exudate under cntrl. 9 Select the cmpressin bandage system t be used based n yur patients level f mbility. Guide t absrbent pad selectin Guide t cmpressin bandage selectin Prduct guide K Tw Prduct guide - Actic Versin

13 10 6 week re- assessments Every 6 weeks trace/ map wund and wrk ut surface area in cm². Wrk ut % reductin ver past 6 weeks. If the wund has nt reduced by 40% then mve patient t the cmplex leg ulcer pathway and refer patient t tissue viability Once healed enter healed ulcer cde n RiO and cmmence patient n a healed leg care plan Guide t wrking ut surface area f wunds Tissue viability referral frm Cmplex leg ulcer pathway algrithm Tissue viability referral frm Standard perating prcedure fr entering leg ulcer cdes n RIO Versin

14 Venus Leg Ulcer Pathway 2 (Cmplex) 24 week healing target (Please refer t the guidance n the reverse f this pathway algrithm) Initial leg ulcer Assessment Diagnsis f venus ulceratin (ABPI ) Enter assessment cde & venus leg ulcer cde n RIO Ulcer present fr mre than 6 mnths If free frm devitalised tissue and/ r infectin Wund slughy (Refer t AMBL tl fr guidance) If lcal wund infectin present (with r withut slugh) Refer t AMBL tl Treat with Antimicrbial dressing as per frmulary, absrbent pad & apprpriate cmpressin fr 2 weeks. If debridement nt achieved within 2 weeks then refer t Tissue Viability fr advice Treat with Antimicrbial dressing as per frmulary, absrbent pad & apprpriate cmpressin fr 2 weeks. Refer t T.V if wund still appears infected after 2 weeks Treat with UrgStart cntact, absrbent pad & apprpriate cmpressin 6 week assessment Has there been a wund area reductin f 20% r mre since initiating Urgstart? YES NO Cntinue with Urgstart Discntinue Urgstart cntact and change t Atrauman Reassess at 12 weeks Discntinue Urgstart and change t Atrauman *If <40% wund reductin since last measurement, refer t tissue viability Refer t Tissue Viability Reassess at 18 weeks - cntinue with Atrauman *If <40% wund reductin since last measurement, refer t Tissue Viability Week 24 week assessment Cntinue with current treatment regime until healed. If wund fails t prgress r becmes static then refer t tissue viability. Once healed, enter healed cde n Ri and cmmence well leg care plan. Versin

15 Guidance fr cmplex venus leg ulcer pathway (See criteria fr pathway allcatin) All f the supprting dcumentatin can be accessed/ dwnladed frm the tissue viability prtal n the intranet. Actin t be taken Dcuments/Guidance/ tls t N supprt actin 1 Venus aetilgy shuld be established by carrying ut a full leg ulcer assessment which shuld include a Dppler assessment. Make sure yu have traced the ulcer/s and wrked ut surface area in cm² Dcument assessment findings in patients ntes Leg ulcer plicy & guidelines Leg ulcer assessment frm Wund prgressin chart Guide t measuring wund surface area Lwer limb assessment frm Allcate this pathway if ulcer is greater than 6 mnths ld, ulcers ttal mre than 100cm²in size and there have been at least 3 episdes f lcal infectin in 6 mnths. 2 Dppler assessment - Ensure ABPI is between befre implementing pathway NB. Cnsider ptential fr falsely elevated readings In the elderly & pts with diabetes r renal disease. Dppler assessment frm Wund healing algrithm/ risk tl Guide t carrying ut a Dppler Guide t interpreting ABPI 3 Enter leg ulcer assessment and venus leg ulcer cde n RiO Standard perating prcedure fr using leg ulcer cdes n RiO Allcate patient t PSAG (Pt Status at a Glance) bard PSAG advice sheet 4 Assess wund bed fr signs f slugh r lcal wund bed infectin Guidance fr the assessment & management f bacterial lading in wunds AMBL tl fr assessing fr lcal infectin 5 If wund bed is slughy r lcally infected cmmence 2 weeks curse Antimicrbial frmulary f a tpical antimicrbial treatment. Antimicrbial frmulary summary sheet 1 st line Hney Inf sheet Patients guide t Hney 2 nd line Cadexmer idine Prduct Inf sheets Dressings These prducts need prescribing (Nt available frm ONPOS). Only Gd prescribing guidance. prescribe the number f dressings required fr a 2 week curse. Dcument start and stp dates f treatment in patient s ntes. 6 If wund is free frm slugh r infectin cmmence Urgstart cntact. Urgstart advice sheet This is a prtease inhibitr that reduces the high level f harmful Guide t MMPs MMPs (enzymes) that are cmmnly ccurring in chrnic wunds. This prduct needs prescribing (Nt available frm ONPOS) 7 Chse an absrbent pad as a secndary dressing based n the level Guide t absrbent pad selectin f exudate present in the wund. NB If yu have t step up t Srbin, this is 2 nd line s will need t be prescribed. 8 Select the cmpressin bandage system t be used based n yur Guide t cmpressin bandage selectin patients level f mbility. Prduct guide K Tw Prduct guide - Actic 9 6 week re- assessment Guide t wrking ut surface area f wunds At 6 weeks trace/ map wund and wrk ut surface area in cm². Wrk ut % reductin ver past 6 weeks. If the wund has nt reduced by 20% then stp the Urgstart cntact, change t Atrauman and refer patient t tissue viability. If 20% + has been achieved cntinue with Urgstart cntact. Tissue viability referral frm week assessment Re assess wund and trace/ map and wrk ut surface area in cm². Stp Urgstart cntact and change primary dressing t Atrauman(Urgstart cntact shuld nly be used fr 12 weeks maximum) If the wund has nt prgressed by 40% refer t tissue viability week + re- assessments Cntinue t re-assess wund/s every 6 weeks, wrking ut surface area in cm². If the wund/s fail t prgress r becme static then refer t tissue viability. Once healed enter healed cde in RiO and cmmence patient n a healed leg care plan Guide t wrking ut surface area f wunds Atrauman prduct guide Tissue viability referral frm Guide t wrking ut surface area f wunds. Tissue viability referral frm Standard perating prcedure fr using leg ulcer cdes n RiO Versin

Commissioning Policy: South Warwickshire CCG (SWCCG)

Commissioning Policy: South Warwickshire CCG (SWCCG) Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding

More information

Swindon Joint Strategic Needs Assessment Bulletin

Swindon Joint Strategic Needs Assessment Bulletin Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical

More information

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018 Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment

More information

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)

More information

Referral Criteria: Inflammation of the Spine Feb

Referral Criteria: Inflammation of the Spine Feb Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses

More information

University College Hospital. Pump school Starting on an insulin pump. Children and Young People s Diabetes Service

University College Hospital. Pump school Starting on an insulin pump. Children and Young People s Diabetes Service University Cllege Hspital Pump schl Starting n an insulin pump Children and Yung Peple s Diabetes Service 2 If yu wuld like this dcument in anther language r frmat, r require the services f an interpreter,

More information

This standard operating procedure applies to stop smoking services provided by North 51.

This standard operating procedure applies to stop smoking services provided by North 51. Authr Name/Title Melanie McIlvar, Bid Develpment Manager Authr Signature Date: 4 th September 2017 Apprver Name/Title Jasn Shelley, Grup Directr f QA/RA Apprver Signature Date: 4 th September 2017 Issue

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

US Public Health Service Clinical Practice Guidelines for PrEP

US Public Health Service Clinical Practice Guidelines for PrEP Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S

More information

TOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH

TOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,

More information

Completing the NPA online Patient Safety Incident Report form: 2016

Completing the NPA online Patient Safety Incident Report form: 2016 Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject

More information

Bedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review:

Bedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review: Bedfrdshire and Hertfrdshire DRAFT Pririties frum statement Number: Subject: Prstatism Date f decisin: January 2010 Date f review: Referral criteria Mst men with lwer urinary tract symptms due t benign

More information

Significance of Chronic Kidney Disease in 2015

Significance of Chronic Kidney Disease in 2015 1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019

More information

Pain relief after surgery

Pain relief after surgery Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read

More information

Immunisation and Disease Prevention Policy

Immunisation and Disease Prevention Policy Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries

More information

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results

More information

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select

More information

Cardiac Rehabilitation Services

Cardiac Rehabilitation Services Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin

More information

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health

More information

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer

More information

Obesity/Morbid Obesity/BMI

Obesity/Morbid Obesity/BMI Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin

More information

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.

More information

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this

More information

DRAFT Policy for the Management of Ear Wax

DRAFT Policy for the Management of Ear Wax Clinical Cmmissining Grup (CCG) Treatment Plicy NHS Birmingham and Slihull Clinical Cmmissining Grup NHS Sandwell and West Birmingham Clinical Cmmissining Grup DRAFT Plicy fr the Management f Ear Wax 1

More information

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...

More information

Annex III. Amendments to relevant sections of the Product Information

Annex III. Amendments to relevant sections of the Product Information Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t

More information

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,

More information

Hospital Preparedness Checklist

Hospital Preparedness Checklist Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been

More information

Podcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10

Podcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10 Pdcast Transcript Title: Cmmn Miscding f LARC Services Impacting Revenue Speaker Name: Ann Finn Duratin: 00:16:10 NCTCFP: Welcme t this pdcast spnsred by the Natinal Clinical Training Center fr Family

More information

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

Human papillomavirus (HPV) refers to a group of more than 150 related viruses. HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between

More information

BRCA1 and BRCA2 Mutations

BRCA1 and BRCA2 Mutations BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease

More information

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals. 27 March 2014 Prfessr Debra Picne Chief Executive Officer Australian Cmmissin n Safety and Quality in Health Care c/ Ms Jennifer Hill, Senir Prject Officer Level 5, 255 Elizabeth Street SYDNEY NSW 2000

More information

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations Implementatin f G6PD testing and radical cure in P. vivax endemic cuntries: cnsideratins Malaria Plicy Advisry Cmmittee Geneva, Switzerland 16-18 September 2015 1 WHO Guidelines n Radical Cure WHO guidelines

More information

Assessment criteria for Primary Health Disciplines Eligibility for Recognition as Credentialled Diabetes Educator. December 2015 ADEA

Assessment criteria for Primary Health Disciplines Eligibility for Recognition as Credentialled Diabetes Educator. December 2015 ADEA Assessment criteria fr Primary Health Disciplines Eligibility fr Recgnitin as Credentialled Diabetes Educatr December 2015 ADEA ASSESSMENT CRITERIA FOR PRIMARY HEALTH DICIPLINES ELIGIBILITY FOR RECOGNITION

More information

Getting Started. Learning Guide. with Continuous Glucose Monitoring for the MiniMed 530G with Enlite. CGM Foundations

Getting Started. Learning Guide. with Continuous Glucose Monitoring for the MiniMed 530G with Enlite. CGM Foundations Getting Started with Cntinuus Glucse Mnitring fr the MiniMed 530G with Enlite Learning Guide CGM Fundatins Cntinuus Glucse Mnitring Learning Guide MiniMed 530G with Enlite - Cntinuus Glucse Mnitring Settings

More information

Alcohol & Substance Misuse Policy. St Mary s CE Academy Trading Company. Date: Spring 2017 Date of Next Review: Summer 2018

Alcohol & Substance Misuse Policy. St Mary s CE Academy Trading Company. Date: Spring 2017 Date of Next Review: Summer 2018 St Mary s CE Academy Trading Cmpany Alchl & Substance Misuse Plicy Date: Spring 2017 Date f Next Review: Summer 2018 Signed by: Family Supprt Crdinatr Signed by: Grup Manager Alchl and Substance Misuse

More information

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer

More information

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED

More information

(Please text me on once you have submitted your request online and the cell number you used)

(Please text me on once you have submitted your request online and the cell number you used) Dear Thank yu fr yur email, nted. Belw steps n hw t register as a service prvider. Please nte that nce yu have requested t becme a service prvider, yu need t sms/what s up me n 0826392585, in rder t activate

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY

More information

Improving Surveillance and Monitoring of Self-harm in Irish Prisons

Improving Surveillance and Monitoring of Self-harm in Irish Prisons HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June

More information

For our protection, we require verification that you have received this notice. Therefore, please sign below.

For our protection, we require verification that you have received this notice. Therefore, please sign below. PATIENT INFORMATION Dear Patient: Sleep prblems are extremely cmmn. Public health and safety are threatened by the increasing prevalence f bstructive sleep apnea, which nw afflicts at least 25 millin adults

More information

Instructions regarding referral of patients to the Persistent Pain Service

Instructions regarding referral of patients to the Persistent Pain Service Prtsmuth Persistent Pain Service Lng Term Cnditins Suite Grund Flr, Blck A St Mary s Cmmunity Health Campus Miltn Rad Prtsmuth Hampshire PO3 6AD Tel: 23 9268 485 Fax: 23 9268 21 Dear GP Instructins regarding

More information

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están

More information

A. Catalonia World Health Organization Demonstration Project

A. Catalonia World Health Organization Demonstration Project A. Catalnia Wrld Health Organizatin Demnstratin Prject In 1989, the Health Department f Catalnia (Spain) and the Cancer Unit at the WHO (Geneva) designed and planned a demnstratin prject fr implementatin

More information

Lower Extremity Amputation (LEA) Considerations / Issues

Lower Extremity Amputation (LEA) Considerations / Issues Lwer Extremity Amputatin (LEA) Cnsideratins / Issues Prviding Te Fillers can be an advantageus resurce fr yur patient and business but it als cmes with certain cnsideratins. Please review this list belw

More information

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management

More information

Generic Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations

Generic Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment

More information

OTHER AND UNSPECIFIED DISORDERS

OTHER AND UNSPECIFIED DISORDERS OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...

More information

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care. Dental Benefits Under the TeamstersCare Plan, yu and yur eligible dependents have three basic ptins when yu need dental care. Optin #1: TeamstersCare Dentists. Yu can use ur in-huse Charlestwn, Chelmsfrd,

More information

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE 2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizatins, Clinical Cascade Breakut Sessin TB/HIV EXERCISE Created by the ICPI TB/HIV Wrkstream Abut this Handut

More information

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder? updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health

More information

Meaningful Use Roadmap Stage Edition Eligible Hospitals

Meaningful Use Roadmap Stage Edition Eligible Hospitals Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing

More information

WHAT IS HEAD AND NECK CANCER FACT SHEET

WHAT IS HEAD AND NECK CANCER FACT SHEET WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice

More information

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher: Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:

More information

CDC Influenza Division Key Points MMWR Updates February 20, 2014

CDC Influenza Division Key Points MMWR Updates February 20, 2014 CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February

More information

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS) Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember

More information

FOLLOW-UP IN-DEPTH INTERVIEW GUIDELINES

FOLLOW-UP IN-DEPTH INTERVIEW GUIDELINES Appendix h STUDY NUMBER: COST OF UNSAFE ABORTION FOLLOW-UP IN-DEPTH INTERVIEW GUIDELINES T be administered abut 2-3 weeks after leaving the health facility 1. IDENTIFICATION 101. Patient identificatin

More information

NIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO

NIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram

More information

The data refer to persons aged between 15 and 54.

The data refer to persons aged between 15 and 54. Drug-related hspital stays in Australia 1993-2005 Prepared by Amanda Rxburgh and Luisa Degenhardt, Natinal Drug and Alchl Research Centre Funded by the Australian Gvernment Department f Health and Ageing

More information

Lee County Florida Income Guideline Chart

Lee County Florida Income Guideline Chart NEIGHBORHOOD STABILIZATION PROGRAM OF LEE COUNTY BUYER-RELATED QUESTIONS 1. Why is NSP beneficial t yur buyers? Three key advantages make the NSP Prgram especially attractive t eligible buyers: 1) Investrs

More information

Postoperative Anterior Cruciate Ligament Reconstruction Care WITH meniscus repair:

Postoperative Anterior Cruciate Ligament Reconstruction Care WITH meniscus repair: Pstperative Anterir Cruciate Ligament Recnstructin Care WITH meniscus repair: Imprtant Phne Numbers: - Please see the cntact infrmatin abve fr imprtant phne numbers t call. - If yu have cncerns after hurs,

More information

CALVIN JOHNSON JR. FOUNDATION 2015 PANCREATIC CANCER RESEARCH SCHOLARSHIP

CALVIN JOHNSON JR. FOUNDATION 2015 PANCREATIC CANCER RESEARCH SCHOLARSHIP I. Intrductin CALVIN JOHNSON JR. FOUNDATION 2015 PANCREATIC CANCER RESEARCH SCHOLARSHIP The Calvin Jhnsn Jr. Fundatin, Inc. (CJJRF) is a nn-prfit 501(c)(3) rganizatin funded in 2008 by Calvin MEGATRON

More information

PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS

PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards

More information

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre

More information

A Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013

A Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013 A Unified Apprach t Cnflict Mineral Cmpliance fr the Tungsten Industry The Westin, Sydney, 23 September 2013 Backgrund Cmpliance f public US dwnstream tungsten users with the reprting requirements f the

More information

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator British Sign Language (BSL) Plan 2018-2024 Octber 2018 Scttish Charity Regulatr Cntents Sectin 1: Intrductin and cntext 1.1 Intrductin 1.2 Our wrk and what we d Sectin 2: Our BSL Plan 2.1 Scttish Public

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...

More information

Interpretation. Historical enquiry religious diversity

Interpretation. Historical enquiry religious diversity Name: Year 8 Histry Prject 3: D The Cmmnwealth Games Still Matter In The 21 st Century? Mdule: Date Set: Deadline: Descriptin f the task: The prject is split int three separate parts: The prject is split

More information

Pediatric and adolescent preventive care and HEDIS *

Pediatric and adolescent preventive care and HEDIS * Pediatric and adlescent preventive care and HEDIS * * HEDIS is a registered trademark f the Natinal Cmmittee fr Quality Assurance (NCQA). UniCare Health Plan f West Virginia, Inc. Healthcare Effectiveness

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic

More information

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights. HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,

More information

Evaluation of a Shared Decision Making Intervention between Patients and Providers to Improve Menopause Health Outcomes: Issue Brief

Evaluation of a Shared Decision Making Intervention between Patients and Providers to Improve Menopause Health Outcomes: Issue Brief Evaluatin f a Shared Decisin Making Interventin between Patients and Prviders t Imprve Menpause Health Outcmes: Issue Brief Key Findings Tablet technlgy can be successfully incrprated int primary practices

More information

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU

More information

Summary Report. Introduction and setting the scene Autilia Newton, Public Health England, Health & Justice Acting Deputy Director

Summary Report. Introduction and setting the scene Autilia Newton, Public Health England, Health & Justice Acting Deputy Director Summary Reprt Having identified Liverpl and the surrunding areas in Merseyside and Cheshire as ne f the highest prevalence areas fr hepatitis C in England, HCV Actin and Public Health England staged the

More information

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps. NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting

More information

ACRIN 6666 Screening Breast US Follow-up Assessment Form

ACRIN 6666 Screening Breast US Follow-up Assessment Form Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related

More information

Record of Revisions to Patient Tracking Spreadsheet Template

Record of Revisions to Patient Tracking Spreadsheet Template Recrd f Revisins t Patient Tracking Spreadsheet Template Belw is a recrd f revisins made by the AIMS Center t the Patient Tracking Spreadsheet Template. The purpse f this dcument is t infrm spreadsheet

More information

Injury, Incident & Illness Procedure

Injury, Incident & Illness Procedure Injury, Incident & Illness Prcedure Injury / Incident Includes any child, adult, r emplyee injured n site. A first aid kit will be available at all times. It will be maintained in accrdance with criterin

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...

More information

Chapter 6: Impact Indicators

Chapter 6: Impact Indicators Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the

More information

QUALITY AND SAFETY MEASURES UPDATE January 2016

QUALITY AND SAFETY MEASURES UPDATE January 2016 CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:

More information

DISCUSSION DRAFT DEVENTER, OCTOBER 2006 Consolidation of documents due for revision

DISCUSSION DRAFT DEVENTER, OCTOBER 2006 Consolidation of documents due for revision UNION EUROPÉENNE DES MÉDECINS SPÉCIALISTES DISCUSSION DRAFT DEVENTER, OCTOBER 2006 Cnslidatin f dcuments due fr revisin ARCHIVED: GENEVA, OCTOBER 2007 REPORT OF THE UEMS SECTION OF PSYCHIATRY Quality Assurance

More information

I am having a Rotator Cuff Repair

I am having a Rotator Cuff Repair I am having a Rtatr Cuff Repair A rtatr cuff repair is surgery t repair a trn tendn in the shulder. The rtatr cuff is a grup f muscles and tendns that frm a cuff ver the shulder jint. The muscles and tendns

More information

Frequently Asked Questions: IS RT-Q-PCR Testing

Frequently Asked Questions: IS RT-Q-PCR Testing Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld

More information

BP Thresholds for Medical Review

BP Thresholds for Medical Review BP Threshlds fr Medical Review Wmen presents t GP pstnatally with high bld pressure r referred t GP by midwife GP t review patient n the same day if BP>150/100. If BP (dne by midwife) persistently 140-149/90-99,

More information

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting

More information

Specifically, on page 12 of the current evicore draft, we find the statement:

Specifically, on page 12 of the current evicore draft, we find the statement: Octber 23, 2016 evicre Healthcare Attn: Dr Greg Allen 400 Buckwalter Place Bulevard Blufftn, SC 29910 RE: evicre Draft Onclgy Imaging Guidelines, v 19.0 Gentlepersns: Prstate Cancer Internatinal is a nt-fr-prfit

More information

Osteoporosis Fast Facts

Osteoporosis Fast Facts Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased

More information

Annual Principal Investigator Worksheet About Local Context

Annual Principal Investigator Worksheet About Local Context Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal

More information

Patrick J McGahan, MD Orthopaedic Surgeon Specializing in Sports Medicine/Shoulder Reconstruction Surgery Instructions Hip

Patrick J McGahan, MD Orthopaedic Surgeon Specializing in Sports Medicine/Shoulder Reconstruction Surgery Instructions Hip Patrick J McGahan, MD Orthpaedic Surgen Specializing in Sprts Medicine/Shulder Recnstructin 2801 K St, Ste 330, Sacrament, CA, 95816 (p) 916-733-5049 (f) 916-733-8914 www.patrickmcgahanmd.cm Befre Surgery

More information

EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS

EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS 1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics

More information

You may have a higher risk of bleeding if you take warfarin sodium tablets and:

You may have a higher risk of bleeding if you take warfarin sodium tablets and: MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain

More information

2016 CWA Political Action Fund Administrative Procedures Checklist

2016 CWA Political Action Fund Administrative Procedures Checklist 2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year

More information